Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about C4 THERAPEUTICS, INC.
01/21C4 THERAPEUTICS : Financial Statements - Form 8-K/A
PU
01/10C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb
MT
01/10C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po..
PU
01/10C4 THERAPEUTICS : Corporate Presentation – January 2022
PU
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
GL
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
CI
01/03C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021C4 THERAPEUTICS : CFT7455 ASH Trial-in-Progress Poster Presentation
PU
2021C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) added to NASDAQ Biotechnology Index
CI
2021C4 Therapeutics to Join NASDAQ Biotechnology Index
MT
2021C4 Therapeutics Added to NASDAQ Biotechnology Index
GL
2021BofA Securities Starts C4 Therapeutics at Buy With $54 Price Target
MT
2021C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
PU
2021C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res..
GL
2021BRD9 TPD Summit Presentation
PU
More most relevant news
All news about C4 THERAPEUTICS, INC.
01/21C4 THERAPEUTICS : Financial Statements - Form 8-K/A
PU
01/21C4 THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A)
AQ
01/10C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb
MT
01/10C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po..
PU
01/10C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
01/10C4 THERAPEUTICS : Corporate Presentation – January 2022
PU
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
GL
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
CI
01/03C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021C4 THERAPEUTICS : CFT7455 ASH Trial-in-Progress Poster Presentation
PU
More news
News in other languages on C4 THERAPEUTICS, INC.
01/10C4 Therapeutics déclare que sa position de liquidité est suffisante jusqu'en 2024 ; les..
01/10C4 Therapeutics annonce 2022 étapes clés pour faire progresser le portefeuille de dégra..
2021C4 Therapeutics rejoint l'indice biotechnologique du NASDAQ
2021C4 Therapeutics réduit sa perte au deuxième trimestre et augmente son chiffre d'affaire..
2021C4 Therapeutics propose un placement d'actions ordinaires à 37 $ par action.
2021MISE À JOUR : C4 Therapeutics lance une offre de 4,25 millions d'actions -- Baisse de 10% ..
2021C4 Therapeutics commence à proposer 4,25 millions d'actions -- Baisse de 4 % de l'actio..
2021C4 Therapeutics administre une dose au premier patient d'une étude sur un médicament po..
2021C4 Therapeutics prévoit de poursuivre les études nécessaires à l'obtention d'une autori..
2021C4 Therapeutics engage un cadre de Novartis comme nouveau directeur financier
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
2021BofA Securities Starts C4 Therapeutics at Buy With $54 Price Target
MT
2021C4 THERAPEUTICS : SVB Leerink Starts C4 Therapeutics at Outperform with $67 Price Target
MT
2021C4 THERAPEUTICS : Stifel Starts C4 Therapeutics at Hold With $45 Price Target
MT
2021C4 THERAPEUTICS : Brookline Initiates Coverage on C4 Therapeutics With Buy Rating, $54 Pri..
MT
2021C4 THERAPEUTICS : BMO Capital Adjusts C4 Therapeutics' Price Target to $53 From $55, Keeps..
MT
More recommendations
Press releases
01/21C4 THERAPEUTICS : Financial Statements - Form 8-K/A
PU
01/21C4 THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A)
AQ
01/10C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po..
PU
01/10C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
01/10C4 THERAPEUTICS : Corporate Presentation – January 2022
PU
More press releases
Upcoming event on C4 THERAPEUTICS, INC.